Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07470606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Study acronym: MemoryRT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Mar 2030 → Jul 2030
See other at-risk trials from The University of Texas Health Science Center at San Antonio

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Start date changed from estimate of Mar 2026 to Jul 6, 2026
    • Primary completion pushed from Mar 2030 to Jul 2030
    • Study completion pushed from Mar 2031 to Jul 2031
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 12 of 12 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Trial Details
NCT Number NCT07470606
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions
(from sponsor)		 Brain Tumor
Related terms Brain Neoplasms
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov